 | • レポートコード：MRC2304J0190 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、253ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、世界の着床前遺伝子検査（PGT）市場規模は、2021年518.55百万ドルから2022年に557.55百万ドルへと拡大、その後2027年までに年平均9.81％成長して909.48百万ドルに達する見通しです。本書は、着床前遺伝子検査（PGT）の世界市場を対象とした調査・分析結果を整理したものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別分析（比較ゲノムハイブリダイゼーション、蛍光in situハイブリダイゼーション、次世代シーケンシング、ポリメラーゼ連鎖反応、一塩基多型）、提供別分析（試薬＆消耗品、ソフトウェア＆サービス）、処置別分析（着床前遺伝子診断、着床前遺伝子スクリーニング）、用途別分析（異数性検査、性別識別検査、HLAタイピング検査、単一遺伝子疾患検査、構造的染色体異常検査）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目を掲載しています。なお、本書には、Abbott Laboratories、Agilent Technologies, Inc.、EUROPE IVF International s.r.o.、Genea Limited、Illumina, Inc.、Invicta Genetics、Invitae Corporation、MedGenome Inc.、Natera, Inc.、Ovation Fertility、Oxford Gene Technology IP Limitedなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の着床前遺伝子検査（PGT）市場規模：技術別 - 比較ゲノムハイブリダイゼーションの市場規模 - 蛍光in situハイブリダイゼーションの市場規模 - 次世代シーケンシングの市場規模 - ポリメラーゼ連鎖反応の市場規模 - 一塩基多型の市場規模 ・世界の着床前遺伝子検査（PGT）市場規模：提供別 - 試薬＆消耗品の市場規模 - ソフトウェア＆サービスの市場規模 ・世界の着床前遺伝子検査（PGT）市場規模：処置別 - 着床前遺伝子診断の市場規模 - 着床前遺伝子スクリーニングの市場規模 ・世界の着床前遺伝子検査（PGT）市場規模：用途別 - 異数性検査の市場規模 - 性別識別検査の市場規模 - HLAタイピング検査の市場規模 - 単一遺伝子疾患検査の市場規模 - 構造的染色体異常検査の市場規模 ・世界の着床前遺伝子検査（PGT）市場規模：地域別 - 南北アメリカの着床前遺伝子検査（PGT）市場規模 アメリカの着床前遺伝子検査（PGT）市場規模 カナダの着床前遺伝子検査（PGT）市場規模 ブラジルの着床前遺伝子検査（PGT）市場規模 ... - アジア太平洋の着床前遺伝子検査（PGT）市場規模 日本の着床前遺伝子検査（PGT）市場規模 中国の着床前遺伝子検査（PGT）市場規模 インドの着床前遺伝子検査（PGT）市場規模 韓国の着床前遺伝子検査（PGT）市場規模 台湾の着床前遺伝子検査（PGT）市場規模 ... - ヨーロッパ/中東/アフリカの着床前遺伝子検査（PGT）市場規模 イギリスの着床前遺伝子検査（PGT）市場規模 ドイツの着床前遺伝子検査（PGT）市場規模 フランスの着床前遺伝子検査（PGT）市場規模 ロシアの着床前遺伝子検査（PGT）市場規模 ... - その他地域の着床前遺伝子検査（PGT）市場規模 ・競争状況 ・企業情報 |
The Global Preimplantation Genetic Testing Market size was estimated at USD 518.55 million in 2021 and expected to reach USD 557.55 million in 2022, and is projected to grow at a CAGR 9.81% to reach USD 909.48 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Preimplantation Genetic Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across Comparative Genomic Hybridization, Fluorescence in Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction, and Single-Nucleotide Polymorphism.
Based on Offering, the market was studied across Instruments Services, Reagents and Consumables, and Software and Services.
Based on Procedure Type, the market was studied across Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.
Based on Application, the market was studied across Aneuploidy, Gender Identification, HLA Typing, Single Gene Disorders, Structural Chromosomal Abnormalities, and X-Linked Disorders. The Structural Chromosomal Abnormalities is further studied across Deletions, Duplications, Inversions, and Translocations.
Based on End User, the market was studied across Contract Research and Manufacturing Organizations, Hospitals, Diagnostic Labs, and Service Providers, and Research Laboratories & Academic Institutes.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Connecticut, Florida, Illinois, Maryland, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Preimplantation Genetic Testing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Preimplantation Genetic Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Preimplantation Genetic Testing Market, including Abbott Laboratories, Agilent Technologies, Inc., EUROPE IVF International s.r.o., Genea Limited, Illumina, Inc., Invicta Genetics, Invitae Corporation, MedGenome Inc., Natera, Inc., Ovation Fertility, Oxford Gene Technology IP Limited, PacGenomics, PerkinElmer, Inc., Progenesis Fertility Center, Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, Takara Bio USA, Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., and Yikon Genomics (Shanghai) Co., Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Preimplantation Genetic Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Preimplantation Genetic Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Preimplantation Genetic Testing Market?
4. What is the competitive strategic window for opportunities in the Global Preimplantation Genetic Testing Market?
5. What are the technology trends and regulatory frameworks in the Global Preimplantation Genetic Testing Market?
6. What is the market share of the leading vendors in the Global Preimplantation Genetic Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global Preimplantation Genetic Testing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Significant Incidences of Fetal Abnormalities and need for Healthy & Successful Embryo Implantation
5.1.1.2. Increase in the Rate of Infertility and the Rising Number of Fertility Clinics Worldwide
5.1.1.3. Growing early diagnostic approaches coupled with increasing government support for IVF
5.1.2. Restraints
5.1.2.1. Limitations and Risk Associated with PGT
5.1.3. Opportunities
5.1.3.1. Advancement in the Field of Preimplantation Genetic Analysis
5.1.3.2. Promising Next-Generation Sequencing (NSG) Method for PGT
5.1.4. Challenges
5.1.4.1. Ethical & Social Constraints and Misuse of PGT
5.2. Cumulative Impact of COVID-19
6. Preimplantation Genetic Testing Market, by Technology
6.1. Introduction
6.2. Comparative Genomic Hybridization
6.3. Fluorescence in Situ Hybridization
6.4. Next-Generation Sequencing
6.5. Polymerase Chain Reaction
6.6. Single-Nucleotide Polymorphism
7. Preimplantation Genetic Testing Market, by Offering
7.1. Introduction
7.2. Instruments Services
7.3. Reagents and Consumables
7.4. Software and Services
8. Preimplantation Genetic Testing Market, by Procedure Type
8.1. Introduction
8.2. Preimplantation Genetic Diagnosis
8.3. Preimplantation Genetic Screening
9. Preimplantation Genetic Testing Market, by Application
9.1. Introduction
9.2. Aneuploidy
9.3. Gender Identification
9.4. HLA Typing
9.5. Single Gene Disorders
9.6. Structural Chromosomal Abnormalities
9.7.1. Deletions
9.7.2. Duplications
9.7.3. Inversions
9.7.4. Translocations
9.7. X-Linked Disorders
10. Preimplantation Genetic Testing Market, by End User
10.1. Introduction
10.2. Contract Research and Manufacturing Organizations
10.3. Hospitals, Diagnostic Labs, and Service Providers
10.4. Research Laboratories & Academic Institutes
11. Americas Preimplantation Genetic Testing Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Preimplantation Genetic Testing Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Preimplantation Genetic Testing Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Agilent Technologies, Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. EUROPE IVF International s.r.o.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Genea Limited
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Illumina, Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Invicta Genetics
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Invitae Corporation
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. MedGenome Inc.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Natera, Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Ovation Fertility
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Oxford Gene Technology IP Limited
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. PacGenomics
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. PerkinElmer, Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Progenesis Fertility Center
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Quest Diagnostics Incorporated
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Reproductive Genetic Innovations, LLC
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Takara Bio USA, Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. The Cooper Companies Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Thermo Fisher Scientific Inc.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Yikon Genomics (Shanghai) Co., Ltd.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing